Eli Lilly and Company v. Teva Pharmaceuticals USA Inc.
2:16-cv-00519
Overview
Parties
Defendant
ICOS Corporation NPE (Individual / Inventor)
Represented By
2 Attorneys ListedFinnegan Henderson Farabow Garrett & Dunner LLP (VA)
11955 Freedom Dr, Suite 800
Finnegan Henderson Farabow Garrett & Dunner LLP
901 New York Ave NW, Washington, DC 20001-4413
Teva Pharmaceuticals USA Inc. Operating Company
Represented By
0 Attorneys ListedEli Lilly and Company Operating Company
Represented By
2 Attorneys ListedFinnegan Henderson Farabow Garrett & Dunner LLP (VA)
11955 Freedom Dr, Suite 800
Finnegan Henderson Farabow Garrett & Dunner LLP
901 New York Ave NW, Washington, DC 20001-4413
Court & Judges
Court
District Court, E.D. Virginia (vaed)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 4 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| π PCT International (WIPO) | PCT World Application | View Official Patent → |
Aquestive Therapeutics, Inc. v. ICOS Corporation et al.
Argentum Pharmaceuticals LLC v. ICOS Corporation
Dr. Reddy's Laboratories, Inc. v. ICOS Corporation
MonoSol Rx, LLC v. ICOS Corporation et al.
Mylan Pharmaceuticals Inc. v. ICOS Corporation
IntelGenx Corp. v. ICOS Corporation et al.
Eli Lilly and Company v. Teva Pharmaceuticals USA Inc.
Eli Lilly and Company v. Sun Pharmaceutical Industries, Ltd.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US6943166
Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
|
Filed: 2000-04-26
Issued: 2005-09-13
|
Expired (Term Ended)
Expires: 2020-04-26
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.
Standard Statutory Term β No obviousness-type double patenting noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).